BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:atamparib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of atamparib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07374419-2363@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:atamparib: Phase 1/2 readout est. (NCT07374419)
DESCRIPTION:atamparib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ata
 mparib in Patients With Advanced Solid Tumors\nEstimated primary completio
 n: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atam
 parib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07374419
URL:https://assetmemo.bio/drug/atamparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
